Type of vaccine | Study ID |
Arms (number analyzed) |
Intervention | Nervous system diseases |
RNA‐based vaccine | Thomas 2021 | Intervention (21,926) |
BNT162b2 |
NR |
Control (21,921) |
Placebo |
NR | ||
Frenck 2021 |
Intervention (1131) |
BNT162b2 |
NR | |
Control (1129) |
Placebo |
NR | ||
Walsh 2020 | Intervention (24) |
BNT162b2 |
NR | |
Control (18) |
Placebo |
NR | ||
El Sahly 2021 |
Intervention (15,166) |
mRNA‐1273 | 2 embolic stroke; 0 ischaemic stroke | |
Control (15,151) |
Placebo | 0 embolic stroke; 1 ischaemic stroke | ||
Ali 2021 |
Intervention (2482) |
mRNA‐1273 | NR | |
Control (1238) |
Placebo | NR | ||
Kremsner 2021 | Intervention (2002) |
CVnCoV | NR | |
Control (1980) |
Placebo | NR | ||
Hall 2021 |
Intervention (60) | mRNA‐1273 boost | NR | |
Control (59) |
mRNA‐1273/placebo | NR | ||
Non‐replicating viral vector | Madhi 2021b | Intervention (52) |
ChAdOx1 | 16 |
Control (52) |
Placebo | 10 | ||
Falsey 2021 | Intervention (21,587) |
ChAdOx1 | 34 paresthesia | |
Control (10,792) |
Placebo | 16 paresthesia | ||
Voysey 2021a | Intervention (12,021) |
ChAdOx1 | 1 ischaemic stroke | |
Control (11,724) |
Placebo | 0 ischaemic stroke | ||
Asano 2022 | Intervention (192) |
ChAdOx1 | NR | |
Control (64) |
Placebo | NR | ||
Kulkarni 2021 | Intervention (300) |
SII‐ChAdOx1 | NR | |
Control (100) |
ChAdOx1 | NR | ||
Sadoff 2021a | Intervention (323) |
Ad26.COV2.S | NR | |
Control (163) |
Placebo | NR | ||
Sadoff 2021b |
Intervention (21,895) |
Ad26.COV2.S | NR | |
Control (21,888) |
Placebo | NR | ||
Logunov 2021 | Intervention (16,427) |
Gam‐COVID‐Vac | 0 haemorrhagic stroke; 1 paraesthesia | |
Control (5435) |
Placebo | 1 haemorrhagic stroke; 1 paraesthesia | ||
Inactivated virus | Ella 2021a | Intervention (99) |
BBV152 | NR |
Control (73) |
Adjuvant | NR | ||
Ella 2021b |
Intervention (12,879) |
BBV152 | NR | |
Control (12,874) | Adjuvant | NR | ||
Zhang 2021 | Intervention (24) |
CoronaVac | NR | |
Control (24) | Adjuvant | NR | ||
Zhang 2021 | Intervention | CoronaVac | NR | |
Control | Adjuvant | NR | ||
Bueno 2021 | Intervention (270) |
CoronaVac | NR | |
Control (164) |
Adjuvant | NR | ||
Han 2021 | Intervention (217) |
CoronaVac | NR | |
Control (114) |
Adjuvant | NR | ||
Palacios 2020 | Intervention (6202) | CoronaVac | NR | |
Control (6194) |
Adjuvant | NR | ||
Wu 2021a | Intervention (124) |
CoronaVac | NR | |
Control (74) |
Adjuvant | NR | ||
Al Kaabi 2021 | Intervention (13,464) |
WIV04 Al Kaabi | NR | |
Intervention (13,471) |
HBO2 | NR | ||
Control (13,453) |
Adjuvant | NR | ||
Tanriover 2021 |
Intervention (6646) | CoronaVac | NR | |
Control (3568) | Adjuvant | 1 acute cerebellar infarction | ||
Fadlyana 2021 | Intervention (405) | CoronaVac | 51 | |
Control (135) |
Adjuvant | 20 | ||
Xia 2020 | Intervention (84) | WIBP‐CorV | NR | |
Control (28) |
Adjuvant | NR | ||
Xia 2021 | Intervention (252) | BBIBP‐CorV | NR | |
Control (252) |
Adjuvant | NR | ||
Guo 2021 | Intervention (84) |
WIBP‐CorV | NR | |
Control (28) |
Adjuvant | NR | ||
Protein subunit | Formica 2021 | Intervention (258) |
NVX‐CoV2373 | 5 |
Control (255) |
Placebo | 4 | ||
Keech 2020 | Intervention (29) |
NVX‐CoV2373 | NR | |
Control (23) |
Placebo | NR | ||
Shinde 2021 | Intervention (484) |
NVX‐CoV2373 | 0 | |
Control (484) |
Placebo | 1 | ||
Heath 2021 | Intervention (7569) |
NVX‐CoV2373 | 32 | |
Control (7570) |
Placebo | 31 | ||
Dunkle 2021 | Intervention (19,965) |
NVX‐CoV2373 | 2 stroke | |
Control (9984) |
Placebo | 0 stroke | ||
Toledo‐Romani 2021 | Intervention (14,675) |
FINLAY‐FR‐2 | NR | |
Intervention (14,679) |
FINLAY‐FR‐2/boostwe FR‐1 | NR | ||
Control (14,677) |
Placebo | NR | ||
Homologous versus heterologous scheme |
Li 2021a | Intervention (51) |
CoronaVac/Ad5 | NR |
Control (50) |
CoronaVac | NR | ||
Liu 2021 |
Intervention (115) |
ChAdOx1/BNT162b2 | NR | |
Control (114) |
ChAdOx1/ ChAdOx1NR |
NR | ||
Intervention (119) |
BNT162b2/ChAdOx1 | NR | ||
Control (115) |
BNT162b2/BNT162b2 | NR | ||
Homologous or heterologous booster versus heterologous booster |
Bonelli 2021 | Intervention (27) |
ChAdOx1 booster | 0 neurological complications |
Control (28) |
BNT162b2 or mRNA‐1273 booster | 0 neurological complications | ||
Sablerolles 2021 | Control (105) |
Ad26.COV2.S/no booster | NR | |
Intervention (106) |
Ad26/booster | NR | ||
Intervention (112) |
Ad26/booster mRNA‐1273 | NR | ||
Intervention (111) |
Ad26/booster BNT162b2 | NR | ||
Mok 2021 | Intervention (30) |
CoronaVac/booster | NR | |
Control (30) |
CoronaVac/booster BNT162b2 | NR | ||
Li 2021a | Intervention (96) |
CoronaVac/boost Ad5 | NR | |
Control (102) | CoronaVac/booster | NR | ||
NR: not reported; RNA: ribonucleic acid. |